---
title: "Guotai Asset Management sees China innovative drug rally as event-driven rebound after pullback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298901466.md"
description: "Guotai Asset Management characterizes the recent >4% rebound in China's innovative drug and CXO sectors as an event-driven recovery following a pullback. Catalysts included positive clinical updates for PD-1/VEGF bispecifics and B7H3 ADCs, reinforcing market sentiment. The firm anticipates sustained CXO demand due to commercial stockpiling of peptides and ADCs, projecting higher earnings visibility for Q3, though it warns that macroeconomic volatility may disrupt this trend."
datetime: "2026-09-14T10:16:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298901466.md)
  - [en](https://longbridge.com/en/news/298901466.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298901466.md)
generator: "portal-rs"
---

# Guotai Asset Management sees China innovative drug rally as event-driven rebound after pullback

-   Guotai Asset Management flagged a sharp rebound in China’s innovative-drug and CXO complex, with tracked indices up more than 4% at the close. \* WCLC clinical updates drove sentiment, led by stronger interim overall-survival results for a PD-1/VEGF bispecific in first-line NSCLC. \* Positive interim Phase III readouts for a B7H3 ADC in second-line SCLC reinforced “ADC plus lung cancer” positioning, supporting licensing expectations. \* The firm expects CXO demand to hold up as peptides, ADCs, and complex small molecules move into commercial stockpiling and supply. \* Guotai sees higher near-term earnings visibility into third-quarter results, while warning macro volatility could disrupt the trade. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guotai Asset Management Co. Ltd. published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [10 CN Ministries Issue Pharma Industry '15th 5Y' Plan, Targeting Revenue of No Less Than RMB3.5T by 2030](https://longbridge.com/en/news/299397341.md)
- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [BioShanghai Week 2026 Opens -- Joining Forces to Build a Global Biopharmaceutical Innovation Ecosystem](https://longbridge.com/en/news/299542597.md)
- [China's 1H25 Innovative Drug Out-Licensing Deal Value Rises to USD110 Billion, Hitting Fresh Record High](https://longbridge.com/en/news/292464937.md)
- [China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New High](https://longbridge.com/en/news/293168428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**